FDAnews Drug Daily Bulletin

STRATEGIC DIAGNOSTICS ANNOUNCES PARTICIPATION OF BERLEX LABORATORIES, INC. IN ITS GENOMIC ANTIBODIES INITIATIVE

April 21, 2006
A A

Strategic Diagnostics Inc., a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, today announced that Berlex Inc., a U.S. affiliate of Schering AG, Germany, has extended its Services Agreement to include SDI's newly commercialized Genomic Antibodies offering. Under terms of this amended agreement, SDI will provide polyclonal and monoclonal Genomic Antibodies to Berlex. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060420005116&newsLang=en)